Details of the Drug Combination

General Information of Drug Combination (ID: DCBDOQ5)

Drug Combination Name
Ofloxacin Ofloxacin
Indication
Disease Entry Status REF
Acute Male Urinary Tract Infection Phase 3 [1]
Component Drugs Ofloxacin   DM0VQN3 Ofloxacin   DM0VQN3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ofloxacin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [2]
Acute maxillary sinusitis N.A. Approved [2]
Anthrax 1B97 Approved [2]
Bacillary dysentery 1A02 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Bronchitis CA20 Approved [2]
Chancroid N.A. Approved [2]
Chronic tubotympanic suppurative otitis media N.A. Approved [2]
Cystitis GC00 Approved [2]
Latent tuberculosis infection N.A. Approved [2]
Malignant otitis externa caused by Pseudomonas aeruginosa N.A. Approved [2]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Pneumonia CA40 Approved [2]
Prostatitis N.A. Approved [2]
Pyelonephritis N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Streptococcal pneumonia N.A. Approved [2]
Traveler's diarrhea ME05.1 Approved [2]
Urinary tract infection GC08 Approved [2]
Pneumonia caused by chlamydia N.A. Investigative [2]
Ofloxacin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [5]
------------------------------------------------------------------------------------
Ofloxacin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Ofloxacin Interacts with 11 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Phytanoyl-CoA dioxygenase, peroxisomal (PHYH) OTUG4BWA PAHX_HUMAN Decreases Expression [7]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Increases Expression [8]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Increases Expression [8]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Increases Expression [8]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [9]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Decreases Expression [10]
HLA class I histocompatibility antigen, alpha chain E (HLA-E) OTX1CTFB HLAE_HUMAN Affects Expression [11]
Integrin beta-4 (ITGB4) OT28UK84 ITB4_HUMAN Decreases Expression [12]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Decreases Expression [13]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Affects Binding [14]
Rho GTPase-activating protein 45 (ARHGAP45) OTL86FEQ HMHA1_HUMAN Affects Expression [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DOT(s)
Indication(s) of Ofloxacin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [2]
Acute maxillary sinusitis N.A. Approved [2]
Anthrax 1B97 Approved [2]
Bacillary dysentery 1A02 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Bronchitis CA20 Approved [2]
Chancroid N.A. Approved [2]
Chronic tubotympanic suppurative otitis media N.A. Approved [2]
Cystitis GC00 Approved [2]
Latent tuberculosis infection N.A. Approved [2]
Malignant otitis externa caused by Pseudomonas aeruginosa N.A. Approved [2]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Pneumonia CA40 Approved [2]
Prostatitis N.A. Approved [2]
Pyelonephritis N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Streptococcal pneumonia N.A. Approved [2]
Traveler's diarrhea ME05.1 Approved [2]
Urinary tract infection GC08 Approved [2]
Pneumonia caused by chlamydia N.A. Investigative [2]
Ofloxacin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [5]
------------------------------------------------------------------------------------
Ofloxacin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Ofloxacin Interacts with 11 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Phytanoyl-CoA dioxygenase, peroxisomal (PHYH) OTUG4BWA PAHX_HUMAN Decreases Expression [7]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Increases Expression [8]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Increases Expression [8]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Increases Expression [8]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [9]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Decreases Expression [10]
HLA class I histocompatibility antigen, alpha chain E (HLA-E) OTX1CTFB HLAE_HUMAN Affects Expression [11]
Integrin beta-4 (ITGB4) OT28UK84 ITB4_HUMAN Decreases Expression [12]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Decreases Expression [13]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Affects Binding [14]
Rho GTPase-activating protein 45 (ARHGAP45) OTL86FEQ HMHA1_HUMAN Affects Expression [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DOT(s)

References

1 ClinicalTrials.gov (NCT02424461) Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection
2 Ofloxacin FDA Label
3 Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
4 Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab Dispos. 2005 Jun;33(6):803-11. doi: 10.1124/dmd.104.003178. Epub 2005 Mar 15.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
7 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
8 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
9 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
10 Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. Toxicol Lett. 2009 Jan 30;184(2):81-4. doi: 10.1016/j.toxlet.2008.10.017. Epub 2008 Oct 28.
11 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
12 Effects of eight antibacterial agents on cell survival and expression of epithelial-cell- or cell-adhesion-related genes in human gingival epithelial cells. J Periodontal Res. 2004 Feb;39(1):50-8. doi: 10.1111/j.1600-0765.2004.00704.x.
13 Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology (Oxford). 2005 Dec;44(12):1514-7. doi: 10.1093/rheumatology/kei087. Epub 2005 Sep 7.
14 Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021 Jun 30;458:152822. doi: 10.1016/j.tox.2021.152822. Epub 2021 May 28.